Immunovant Inc. (IMVT)
NASDAQ: IMVT
· Real-Time Price · USD
17.41
-0.52 (-2.90%)
At close: Oct 16, 2025, 3:59 PM
17.00
-2.35%
After-hours: Oct 16, 2025, 07:39 PM EDT
-2.90% (1D)
| Bid | 17.41 |
| Market Cap | 3.03B |
| Revenue (ttm) | 160K |
| Net Income (ttm) | -447.3M |
| EPS (ttm) | -2.84 |
| PE Ratio (ttm) | -6.13 |
| Forward PE | -6.12 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 18.48 |
| Volume | 1,805,706 |
| Avg. Volume (20D) | 1,529,760 |
| Open | 18.07 |
| Previous Close | 17.93 |
| Day's Range | 17.11 - 18.34 |
| 52-Week Range | 12.72 - 32.10 |
| Beta | 0.48 |
| Ex-Dividend Date | n/a |
About IMVT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMVT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMVT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
+5.6%
Immunovant shares are trading higher following a Q...
Unlock content with
Pro Subscription
7 months ago
+4.29%
Immunovant shares are trading higher. B of A Securities and Guggenheim reiterated Buy ratings on the stock.
2 months ago · seekingalpha.com
Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst StackRoivant Sciences Ltd.'s Vant model gives it risk-isolated development, monetization flexibility, and diversified optionality. ROIV's main value drivers are Immunovant, Priovant, Pulmovant, and Genevan...
